Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

128.76 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Crispr Therapeutics Ag

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
After-hours buzz: TLRY, RHT & more
See which stocks are posting big moves after the bell on Wednesday. 
Tags CRISPR Therapeutics AG Herman Miller Inc Market Insider
From CNBC.com News
This Gene-Editing Biotech Toppled On A Deal In Diabetes
Crispr Therapeutics stock toppled Monday after the biotech announced a collaboration deal with privately held ViaCyte to work on a gene-edited diabetes treatment. 
From Investor's Business Daily
Is CRISPR Therapeutics AG a Buy?
On one hand, there's the promise of a groundbreaking technology. On the other hand, huge risk. Which hand wins? 
Tags CRSP EDIT Market News
From Motley Fool
Cramer's lightning round: I'm not the call on how to play Roku
Jim Cramer rattles off his take on callers' favorite stocks, including a streaming play that he's gotten wrong in the past. 
Tags At Home Group Inc Investing/Stock Market Markets
From CNBC.com News
UPDATE 2-U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing
A U.S. appeals court on Monday allowed a research center affiliated with the Massachusetts Institute of Technology and Harvard University to keep patents potentially worth billions of dollars on a... 
Tags companyNews
From Reuters: Company News
UPDATE 1-U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing
A U.S. appeals court on Monday allowed a research center affiliated with the Massachusetts Institute of Technology and Harvard University to keep patents potentially worth billions of dollars on a... 
Tags companyNews
From Reuters: Company News
Better Buy: Editas Medicine, Inc. vs. CRISPR Therapeutics
Which stock wins in a one-on-one matchup between these two gene-editing biotechs? 
Tags CRSP EDIT Market News
From Motley Fool
CRSP October 26th Options Begin Trading
Investors in CRISPR Therapeutics AG (CRSP) saw new options become available today, for the October 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP... 
Tags Stocks
From Market News Video
Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock
CRISPR Therapeutics might lead its start-up peers, but its collaboration partner is the better stock to buy. 
Tags Market News CRSP GLPG
From Motley Fool
Here's Why CRISPR Stocks Rose as Much as 18.7% in August
The three leading CRISPR gene-editing companies announced first-half 2018 earnings last month, and received a boost on the final day of August. 
Tags NTLA EDIT CRSP
From Motley Fool
3 Biotech Stocks That Could Soar Next Week
Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week. Here's why. 
Tags AMRN VRTX Market News
From Motley Fool
3 Stocks That Could Put Netflix's Returns to Shame
Netflix went from $3 per share to nearly $400. Could these three stocks do even better? 
Tags VRTX NFLX Market News
From Motley Fool
About to Buy Penny Stocks? Look at These 3 Companies First
The allure of mega-returns can make penny stocks attractive. The reality is, this isn't where you'll find the next Apple or Amazon, and there is far more risk than potential reward. Here are three far... 
Tags TSLA NVEE Market News
From Motley Fool
This Start-up Thinks It Can Tackle One of CRISPR's Biggest Obstacles
CRISPR gene editing has endured a rough 2018 after years of hype. One start-up, which shares founders and tech with Editas Medicine, thinks it can move the field forward. 
Tags NTLA CRSP EDIT
From Motley Fool
Biotech Funds Tack On $510 Million As Inflows Hit Eight-Week Streak
Biotech funds saw $510 million in net inflows this week, as assets increased for the eighth week running, an analyst said Friday. 
From Investor's Business Daily
3 Relatively Safe Ways to Invest in Gene Editing
Here's how you could profit from gene editing without buying the stocks of preclinical-stage biotechs. 
Tags AGN Market News EDIT
From Motley Fool
Interesting CRSP Put And Call Options For October 5th
Investors in CRISPR Therapeutics AG (CRSP) saw new options become available today, for the October 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP... 
Tags Stocks
From Market News Video
The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed
Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold. 
Tags ONCE GILD CRSP
From Motley Fool
45 Biggest Movers From Yesterday
Gainers China Rapid Finance Limited (NYSE: XRF) shares jumped 30.09 percent to close at $2.81 on Thursday after surging 16.13 ... 
Tags News LFVN Movers & Shakers
From Benzinga
31 Stocks Moving In Thursday's Mid-Day Session
Gainers Ferroglobe PLC (NASDAQ: GSM) gained 18 percent to $8.055 after declining 3.12 percent on Wednesday. Ascent Capital ... 
Tags Market News GSM CRSP
From Benzinga
28 Stocks Moving In Thursday's Pre-Market Session
Gainers Ferroglobe PLC (NASDAQ: GSM) rose 24.5 percent to $8.50 in pre-market trading after declining 3.12 percent on ... 
Tags CAAP Trading Ideas Market News
From Benzinga
Biotech Snapshot During A Rally Day: No Summer Doldrums…
Biotech stocks were mixed trading closer to the flatline after the close on light summer volume. Macro issues such as drug pricing, trade and the Fed remain a concern. 
Tags Pharma/Biotech Stocks / Equities Healthcare
From Blogs - TalkMarkets
Is Crispr Therapeutics Stock Grossly Overvalued?
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity? 
Tags CELG CRSP BAYRY
From Motley Fool
Jim Cramer Advises His Viewers On Visa, Zuora And More
On CNBC's "Mad Money Lightning Round", Jim Cramer said he would take profits in Crispr Therapeutics AG (NASDAQ: ... 
Tags mad money Lightning Round TSCO AEP
From Benzinga
Cramer's lightning round: If Zuora's stock dips, buy more
Jim Cramer zooms through his take on callers' favorite stocks, including a play on the growing subscription economy. 
Tags Zuora Inc American Electric Power Company Inc Sientra Inc
From CNBC.com News
3 Top Biotech Stocks to Buy in August
It could be the perfect time to add shares in these biotech companies to portfolios ahead of key catalysts. 
Tags VRTX GLPG CRSP
From Motley Fool
Here's Why CRISPR Therapeutics Lost 18.8% in July
The gene-editing pioneer (and its peers) faced more pressure from a study highlighting the unknowns of CRISPR tools. 
Tags Market News CRSP
From Motley Fool
Sum Up The Parts: FAD Could Be Worth $79
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue
The biotech benefits from economies of scale. 
Tags VRTX Market News CRSP
From Motley Fool
3 Reasons Why Vertex Pharmaceuticals Stock Isn't Nearly as Expensive as It Looks
The market isn't fully appreciating just how much more room this biotech has to grow. 
Tags Market News CRSP VRTX
From Motley Fool
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback